Development and Optimization of Hemostatic Peptides for Hemorrhage Control on Battlefields – Hemostatic Peptides

PDF

Authors
  1. Charbonneau, S.
  2. Blostein, M.D.
Corporate Authors
Defence R&D Canada - Toronto, Toronto ONT (CAN);McGill Univ, Montreal Que (CAN) Lady Davis Institute of Medical Research, Jewish General Hospital
Abstract
The goal of the research contract conducted for the Defence Research and Development Canada – Toronto, was to develop a hemostatic biocompatible surface to treat hemorrhagic injuries sustained on the battlefield. During the first year of the contract, a candidate hemostatic amphipathic helical peptide (an ideal amphipathic helical peptide or IAP) was developed (published in Biochemical Journal 412: 545-51 2008) and different biocompatible surfaces were tested (published in Journal of Biomaterials Research, Part B: Applied Biomaterials, 2008 Sep 5). Once the peptide and biomaterial were identified, the second year was dedicated to testing IAP coupled to different surfaces and we finally settled on IAP coupled to polyethylene glycol and poly(allylamine) (PEG-PAA) for further testing. In vivo work testing this material was carried out on small animals (rabbits) and subsequently on large animals (pigs) during the second and third year. We have data that demonstrates the feasibility of such material to arrest bleeding in vivo by reducing hemorrhage by 40-50%.

Il y a un résumé en français ici.

Keywords
Peptides;Hemorrhage control
Report Number
DRDC-TORONTO-CR-2009-014 — Contractor Report
Date of publication
28 Feb 2009
Number of Pages
37
DSTKIM No
CA032389
CANDIS No
531554
Format(s):
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: